WO2015089495A3 - Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders - Google Patents

Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders Download PDF

Info

Publication number
WO2015089495A3
WO2015089495A3 PCT/US2014/070221 US2014070221W WO2015089495A3 WO 2015089495 A3 WO2015089495 A3 WO 2015089495A3 US 2014070221 W US2014070221 W US 2014070221W WO 2015089495 A3 WO2015089495 A3 WO 2015089495A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
benzylpropionamide
dioxol
benzo
Prior art date
Application number
PCT/US2014/070221
Other languages
French (fr)
Other versions
WO2015089495A2 (en
Inventor
William A. Garland
Jaideep Chaudhary
Glen STOLLER
Original Assignee
Angiogenex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenex, Inc. filed Critical Angiogenex, Inc.
Priority to JP2016558543A priority Critical patent/JP2017506257A/en
Priority to MX2016007748A priority patent/MX2016007748A/en
Priority to EP14870415.8A priority patent/EP3079680A4/en
Priority to CN201480075495.2A priority patent/CN107847470A/en
Priority to AU2014361814A priority patent/AU2014361814A1/en
Publication of WO2015089495A2 publication Critical patent/WO2015089495A2/en
Publication of WO2015089495A3 publication Critical patent/WO2015089495A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides methods for impairing function or reducing or ablating levels of Id (inhibitors of differentiation) proteins to suppress metastasis of cancer cells in mammalian subjects presenting with cancer or elevated risk of metastatic disease. Exemplary anti-Id compounds include N-(3-(benzo[d] [1,3]dioxol-5-yl)-3-(2-methoxyphenyl)propyl)-N- benzylpropionamide and isolated enantiomers of N-(3-(benzo[d] [ 1,3]dioxol-5-yl)-3-(2- methoxyphenyl)propyl)-N-benzylpropionamide. Anti-Id compositions and methods of the invention can be combined with standard anticancer treatment modalities, such as surgery, radiation and chemotherapy. Also provided are compositions and methods to treat other hyperproliferative disorders, including pathogenic angiogenic conditions, including tumor-associated neoangiogenesis and ocular vascular pathologies including age-related macular degeneration.
PCT/US2014/070221 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders WO2015089495A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2016558543A JP2017506257A (en) 2013-12-13 2014-12-14 Compositions and methods for the treatment, prevention and diagnosis of cancer and other proliferative diseases
MX2016007748A MX2016007748A (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders.
EP14870415.8A EP3079680A4 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
CN201480075495.2A CN107847470A (en) 2013-12-13 2014-12-14 For treating, preventing and diagnosing the composition and method of cancer and other proliferative diseases
AU2014361814A AU2014361814A1 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361916116P 2013-12-13 2013-12-13
US61/916,116 2013-12-13
US201461965776P 2014-02-06 2014-02-06
US61/965,776 2014-02-06

Publications (2)

Publication Number Publication Date
WO2015089495A2 WO2015089495A2 (en) 2015-06-18
WO2015089495A3 true WO2015089495A3 (en) 2015-11-12

Family

ID=53371974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/070221 WO2015089495A2 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Country Status (6)

Country Link
EP (1) EP3079680A4 (en)
JP (2) JP2017506257A (en)
CN (1) CN107847470A (en)
AU (1) AU2014361814A1 (en)
MX (1) MX2016007748A (en)
WO (1) WO2015089495A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000548B2 (en) * 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3285877B1 (en) 2015-04-21 2022-10-19 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
LU100900B1 (en) * 2018-08-10 2020-02-17 Thomas Melchior Homann COMPOUNDS FOR MODULATING A-KETOGLUTARIC ACID (2KG) -DEPENDENT OXYGENASES
EP3760614B8 (en) * 2019-07-02 2022-04-27 Universität Heidelberg Chemical inhibitors of id proteins for the treatment of cancer and other diseases
CN113627763B (en) * 2021-07-30 2023-12-01 厦门大学 Risk quantization evaluation model building method
CN114480490A (en) * 2021-12-31 2022-05-13 四川省医学科学院·四川省人民医院 Method for constructing animal model of retinal neovascular diseases
CN115487358B (en) * 2022-08-05 2023-05-30 核工业四一六医院 Gel composite scaffold for cartilage tissue repair and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226422A1 (en) * 2007-10-16 2009-09-10 Jaideep Chaudhary Chemical Inhibitors of Inhibitors of Differentiation
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000036A1 (en) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226422A1 (en) * 2007-10-16 2009-09-10 Jaideep Chaudhary Chemical Inhibitors of Inhibitors of Differentiation
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM. [o] 24 June 2015 (2015-06-24), Database accession no. 79254004 *

Also Published As

Publication number Publication date
MX2016007748A (en) 2017-07-28
JP2017506257A (en) 2017-03-02
EP3079680A4 (en) 2017-11-22
CN107847470A (en) 2018-03-27
JP2019203028A (en) 2019-11-28
WO2015089495A2 (en) 2015-06-18
EP3079680A2 (en) 2016-10-19
AU2014361814A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
WO2015089495A3 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
PH12018500554A1 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
MX2016010519A (en) Compounds for treating patients with ros1 mutant cancer cells.
EA201391416A1 (en) NEW CONNECTIONS AS PROTEINKINASE MODULATORS
EA201291098A1 (en) NEW CONNECTIONS OF 3,5-DESIGNED-3H-IMIDAZO [4,5-B] Pyridine and 3,5-DESIGNED -3H- [1,2,3] TRIAZOLO [4,5-B] Pyridine as modulators of protein kinase
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MY195669A (en) 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer
CL2012000592A1 (en) Compounds derived from phenoxy or phenyl-thieno [3,2-b] pyridine, tyrosine kinase inhibitors; pharmaceutical composition; and its use in the treatment of colorectal, lung, hematological, liver, breast cancer, in diabetic retinopathy, macular degeneration, glaucoma, psoriasis, diabetes, neurodegenerative diseases, among others.
WO2014018881A8 (en) Atx modulating agents
WO2015050989A3 (en) Macrocyclic compounds for the treatment of proliferative diseases
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
EA201790267A1 (en) NEW KINAZ MODULATORS
WO2014100620A3 (en) Compounds and methods for kinase modulation, and indications therefor
WO2014039714A3 (en) Compounds and methods for kinase modulation, and indications therefor
WO2017182783A3 (en) Inactivation of dna repair as an anticancer therapy
MX2014013090A (en) Pyrrolotriazinone derivatives.
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
NZ704863A (en) Bicyclic pyridinones useful as gamma secretase modulators
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PH12014502166A1 (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
MX362939B (en) (aza-)isoquinolinone derivatives.
EA201890449A1 (en) FUMAGILLINUM HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
MX2018014718A (en) Compounds and their use for reducing uric acid levels.
MX349550B (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14870415

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016558543

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/007748

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2014870415

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014870415

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014361814

Country of ref document: AU

Date of ref document: 20141214

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14870415

Country of ref document: EP

Kind code of ref document: A2